Vost Effectiveness of Blinatumomab Vs Inotuzomab Ozogamicin (INOTUZUMAB) in Adult Patients with Relapsed or Refracory (R/R) Acute Lymphoblastic Leukemia (ALL) with Zero or One Prior Salvage Therapy (S0/S1) from a US Payer Perspective
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1711
https://www.valueinhealthjournal.com/article/S1098-3015(18)32033-3/fulltext
Title :
Vost Effectiveness of Blinatumomab Vs Inotuzomab Ozogamicin (INOTUZUMAB) in Adult Patients with Relapsed or Refracory (R/R) Acute Lymphoblastic Leukemia (ALL) with Zero or One Prior Salvage Therapy (S0/S1) from a US Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)32033-3&doi=10.1016/j.jval.2018.04.1711
First page :
Section Title :
Open access? :
No
Section Order :
931